Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. News
  7. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

H Lundbeck A/S : The Hunt for a New Weapon Against Schizophrenia

05/24/2021 EDT

According to Garry Honey, we find ourselves looking at the most complicated engine ever devised. Around the world, Lundbeck is respected for confronting the challenge of working with extremely complicated diseases like schizophrenia and other brain disorders.

Although we haven't been able to identify a biomarker or a set of biomarkers for schizophrenia yet, there is no reason to believe, that we won't find biomarkers for schizophrenia and other psychiatric diseases within the next ten years.

'I believe that this will happen, due to the convergence of several developments. We have made enormous strides in understanding brain function and have incredible tools at our disposal that are now maturing and generating new, meaningful insights,' says Garry Honey.

Garry Honey confidently believes, that the technical progression combined with three significant developments will pave the way for innovation within biomarkers in schizophrenia and other brain diseases:

  • The combined effort of the scientific community to develop large databases, such that small studies that can give inconsistent findings can be avoided, and hypotheses can be based on data from thousands of subjects, where these tools have been used to gather data.
  • The ability to utilize the intelligent devices all around us: the smartphones, the tablets, the smartwatches, the internet-aware devices in our homes, that can collect continuous streams of data, that mean our measurements in clinical trials are no longer brief snapshots in time, but truly reflective of our real-world experience.
  • The rapid expansion in the use of artificial intelligence is leading to new insights, where we can benefit from machine learning to recognise patterns in these new, large bodies of data, that would be difficult to discern by humans.

This potent combination, of large amounts of data, from connected, continuous, intelligent devices, with the analytical tools to leverage it, is opening a huge potential in our understanding of the brain, and the problems that occur when misfiring brain regions result in devastating illnesses like schizophrenia.

Disclaimer

H. Lundbeck A/S published this content on 24 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2021 13:29:04 UTC.


© Publicnow 2021
All news about H. LUNDBECK A/S
09/14HERANTIS PHARMA OYJ : Names Chairman of New Scientific Advisory Board
MT
08/18H LUNDBECK A/S : Drugmaker Lundbeck lowers sales outlook as generic competition ..
RE
08/18H LUNDBECK A/S : Lundbeck continues to deliver solid growth for strategic brands..
AQ
08/18H. Lundbeck A/S Reports Earnings Results for the Second Quarter Ended June 30..
CI
08/04H LUNDBECK A/S : Lundbeck enters strategic research collaboration with Rgenta Th..
PU
08/04Rgenta Therapeutics, Inc. Enters into a Collaboration with H. Lundbeck A/S
CI
07/22H LUNDBECK A/S : What do you mean brain health?
PU
07/01Denovo Biopharma LLC Announces In-Licenses Late-Stage Alzheimer's Disease Ass..
CI
06/15#1VOICESUMMIT : Partnering with the advocacy community to further brain health a..
PU
06/11H LUNDBECK A/S : Lundbeck CEO, Deborah Dunsire, warns that we could be on the br..
PU
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Financials
Sales 2021 16 422 M 2 590 M 2 590 M
Net income 2021 1 453 M 229 M 229 M
Net Debt 2021 2 161 M 341 M 341 M
P/E ratio 2021 23,4x
Yield 2021 1,67%
Capitalization 33 818 M 5 337 M 5 334 M
EV / Sales 2021 2,19x
EV / Sales 2022 1,91x
Nbr of Employees 5 603
Free-Float 30,7%
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 170,20 DKK
Average target price 229,60 DKK
Spread / Average Target 34,9%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders GŲtzsche Chief Financial Officer & Executive Vice President
Lars SÝren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-18.49%5 337
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604